Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, discusses his recent publication on the use of classical chemotherapy and stem cell support to bridge patients with relapsed/refractory multiple myeloma (R/R MM) to subsequent treatments. Dr Richter notes that many heavily pretreated patients do not fit the inclusion criteria for cellular therapy trials due to bone marrow compromise. However, data suggests that short-term classical chemotherapy treatment and stem cell support may promote sufficient marrow recovery for further treatment and clinical trial inclusion. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
